Abstract
Gonadotrophin releasing hormone agonist with low dose human chorionic gonadotrophin co-triggers versus gonadotrophin releasing hormone agonist alone for reducing the risk of ovarian hyperstimulation in women with polycystic ovarian disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have